NysnoBio
Sarah Dunham Finley has over two decades of work experience in the pharmaceutical and biotechnology industry. Sarah is currently serving as a project manager at NysnoBio since September 2019. Prior to this, Sarah worked at Genentech as a Clinical Trial Associate from January 2007 to October 2009. Sarah also had a role of Clinical Trials Coordinator at the Centre for Clinical Studies, Nucleus Network from January 2006 to November 2006. Sarah's earlier experience includes working as a Senior Research Associate, Medicinal Chemistry at Theravance from January 2000 to January 2005, and as a Research Assistant at Tularik from December 1998 to January 2000.
Sarah Dunham Finley attended Bates College from 1989 to 1993, where they obtained a Bachelor of Science degree in Chemistry.
This person is not in any teams
NysnoBio
NysnoBio was the first to discover the Parkin gene, which has been related to Parkinson's disease. They were the first to show Parkin is an E3 ubiquitin ligase, the first to publish a crystal structure proving essential parts of enzymology, the first to use AAV in gene therapy, and in clinical neuroimaging, ensuring decisive outcomes in theclinic.